FDA Approves Elahere (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer

Elahere is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin® Use VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news